Gynecologic Oncologist

Adam C. ElNaggar, MD

Specialty Area
Gynecologic Oncology   |   Medical Oncology
East Campus
7945 Wolf River Boulevard
Germantown TN 38138 901.683.0055
405 East Jackson Avenue
Jonesboro AR 72401 870.207.8177
1588 Union Avenue
Memphis TN 38104 901.683.0055
Dr. ElNaggar is Assistant Professor of Gynecologic Oncology at the University of Tennessee Health Science Center (UTHSC) and Director of Gynecologic Cancer Research at the West Cancer Center. He completed his residency at UTHSC in Memphis, TN and completed his fellowship at The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solve Research Institute (OSU) in Columbus, OH. His research focus as a Gynecologic Oncology fellow was in the development of novel therapeutics for ovarian cancer, specifically the role of the STAT3 pathway in tumorigenesis and creating targeted therapies. Prior to fellowship, he did laboratory research on gene regulation in postimplation murine embryos and clinical research focusing on clinical outcomes and lower genital tract disease. He has worked under the mentorship of Drs. Karuppaiyah Selvendiran (basic science) and David Cohn (translational research) at OSU, and Drs. Lawrence Pfeffer and Ramesh Narayanan (basic science) at UTHSC-West Cancer Center. While a fellow at OSU, he received the 2013 Roy M. Pitkin award, which is awarded to the most outstanding articles in Obstetrics & Gynecology during the past year. Since beginning at University of Tennessee-West Cancer Center, Dr. ElNaggar has led efforts for the West Cancer Center to become main site members of NRG Oncology and GOG, two collaborative research organizations. He serves as the gynecologic disease site principal investigator for NRG, GOG, and SWOG studies, as well as industry sponsored trials.He currently serves on the National Comprehensive Cancer Network (NCCN) ovarian cancer panel and is mentoring two GYN Oncology fellows with Drs. Pfeffer and Narayanan. Projects include understanding the role of 14-3-3-σ and ILK pathways in ovarian cancer and the use of microRNA for the early detection of ovarian cancer. Dr. ElNaggar’s clinical interests include personalized medicine, advanced surgical techniques, and targeted therapies. He is a member of multiple professional societies and committees, both regionally and nationally. He has authored numerous publications and has been highly recognized for outstanding presentations and abstracts.


Anderson University, Anderson, IN


Medical School:

Indiana University School of Medicine


University of Tennessee Health Science Center, Memphis, TN



Ohio State University
Foundation for Gynecologic Oncology Improving Outcomes Research and Education Award 2013 Roy M. Pitkin Award (May 2014) Excellence in Gynecologic Oncology (June 2013) Resident Teaching Award (June 2013) Society of Laparoendoscopic Surgeons Resident Achievement Award (June 2013) North American Menopause Society/Pfizer Medical Resident & Fellow Reporter Award (July 2012) Bradford W. Kincheloe Outstanding Resident Research Award (May 2012) Felix Rutledge Fellow (Nov. 2011)
Gynecologic Oncologist, West Cancer Center Assistant Professor, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center Associate Fellowship Director, Gynecologic Oncology Director of Gynecologic Cancer Research
Areas of Expertise Women’s Cancers Minimally Invasive and Robotic Surgery Investigational Therapeutics Surgical Management of Advanced Gynecologic Cancer Ovarian Cancers Uterine Cancers Endometrial Cancers Cervical Cancers Vaginal Cancers Vulvar Cancers Research Recent areas of focus for Dr. ElNaggar’s research interests include: Clinical outcomes research in endometrial and ovarian cancers, having recently been awarded the Foundation for Gynecologic Oncology Improving Outcomes Research and Education Grant to study quality indicators in ovarian cancer. Investigational therapeutics, where Dr. ElNaggar has worked to develop novel agents for the treatment of gynecologic malignancies, primarily STAT3 inhibition in ovarian cancer, as well as establish new treatment paradigms of targeted agents. Invasive and pre-invasive lower genital tract disease.
To view Dr. ElNaggar’s most recent publications, click here.